Wave Life Sciences Ltd. (NASDAQ:WVE) tinted gains of +0.2% (+0.1 points) to US$49.15. The volume of 0.12 Million shares climbed down over an trading activity of 154.95 Million shares. EPS ratio determined by looking at last 12 month figures is -4.21. Over the same time span, the stock marked US$55.95 as its best level and the lowest price reached was US$15.15. The corporation has a market cap of US$1.41 Billion.
Wave Life Sciences Ltd. (NASDAQ:WVE)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -76.9 percent while most common profitability ratio return on investment (ROI) was -73.9 percent. The company’s institutional ownership is monitored at 82 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.6. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Upland Software, Inc. (NASDAQ:UPLD) is worth US$774.7 Million and has recently risen 0.2% to US$35.07. The latest exchange of 0.14 Million shares is below its average trading activity of 202.96 Million shares. The day began at US$34.99 but the price moved to US$34.99 at one point during the trading and finally capitulating to a session high of US$35.1. The stock tapped a 52-week high of US$36.37 while the mean 12-month price target for the shares is US$35.6.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 7.22, and a price to sales ratio of 7.12. For the past 5 years, the company’s revenue has grown 33.9%, while the company’s earnings per share has grown -28.5%. With an institutional ownership near 57.6%, it carries an earnings per share ratio of -0.9.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.86.